Dashboard
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 0.00% and Operating profit at 0% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at 0 times
Flat results in Mar 26
Risky - Negative EBITDA
Stock DNA
Pharmaceuticals & Drugs
INR 18 Cr ()
NA (Loss Making)
37
0.00%
0.00
0.00%
-17.61
Total Returns (Price + Dividend) 
Rekvina Labs for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
Announcements 
Announcement under Regulation 30 (LODR)-Open Offer - Updates
01-Aug-2026 | Source : BSEPost offer Newspaper Annoucement
Board Meeting Intimation for Consideration Of Unaudited Financial Result For The Quarter Ended 30Th June 2026
01-Aug-2026 | Source : BSERekvina Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 inter alia to consider and approve Unaudited Financcial Result for the Quarter ended 30th June 2026
Post Offer Advertisement
31-Jul-2026 | Source : BSEVivro Financial Services Pvt Ltd (Manager to the Open Offer) has submitted to BSE a copy of Post Offer Advertisement in accordance with Regulation 18(12) of the Securities Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations 2011as amended (SEBI (SAST) Regulations) with respect to the Open Offer to the Public Shareholders of Rekvina Laboratories Ltd (Target Company).
Corporate Actions 
13 Aug 2026
No Dividend history available
Rekvina Labs Ltd has announced 5:10 stock split, ex-date: 30 Apr 14
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Non Institution
None
Held by 0 Schemes
Held by 0 FIIs
Surbhit Mukesh Shah (15.22%)
Niravbhai Jashubhai Patel (6.47%)
45.86%
Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ
QoQ Growth in quarter ended Mar 2026 is 105.71% vs 75.00% in Dec 2025
QoQ Growth in quarter ended Mar 2026 is 50.00% vs -300.00% in Dec 2025
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 0.00% vs 0.00% in Mar 2025
YoY Growth in year ended Mar 2026 is -78.57% vs -75.00% in Mar 2025